Please assess the completion status of the following clinical trial:

Trial Title: Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria :~* Received Tdap or Tdap-IPV vaccine in study TD9707 or TD9805.~* Never previously received Tdap vaccine and has not received any tetanus-, diphtheria , or pertussis-containing vaccine in the past 10 years.~* Participated in TD9707 or TD9805 but does not meet inclusion/ exclusion criteria or willing to undergo phlebotomy but not willing to receive Tdap (ADACEL®) vaccine.~* Signed Institutional Review Board (IRB)-approved informed consent form~* Able to attend all scheduled visits and to comply with all trial procedures~* For a woman, a negative urine pregnancy test and the use of effective method(s) of contraception, or the inability to become pregnant~Exclusion Criteria :~* Any condition listed as a contraindication in the ADACEL® Canadian product monograph~* Any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the evaluation of the vaccine~* Chronic illness, at a stage that could interfere with trial conduct or completion, in the opinion of the investigator~* Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic (injected or oral) corticosteroid therapy. Individuals on a tapering dose schedule of oral steroids lasting less than 7 days may be included in the trial as long as they have not received more than 1 course within the last 2 weeks prior to enrollment~* Febrile illness (temperature ≥ 37.5°C \[99.5°F\]) at the time of inclusion~* History of documented diphtheria, pertussis, or tetanus disease since participation in studies TD9707 or TD9805. Or history of documented diphtheria, pertussis, or tetanus disease in the last 10 years.~* Known or suspected receipt of a diphtheria-, pertussis-, or tetanus-containing vaccine since participation in study TD9707 or TD9805. For Group 2, known or suspected receipt of a diphtheria-, pertussis-, or tetanus-containing vaccine in the last 10 years.~* Receipt of any vaccine, other than influenza vaccine, in the 28-day period prior to Visit 1 or scheduled to receive any vaccine, other than influenza vaccine, in the period between Visit 1 and Visit 2. For influenza vaccine only, defer if received in the 14 days prior to enrollment or scheduled to receive prior to Visit 2.~* Receipt of blood or blood-derived products in the past 3 months~* Suspected or known hypersensitivity to any of the vaccine components, or a life-threatening reaction after previous administration of the vaccine or a vaccine containing the same substances~* Unable to attend the scheduled visits or to comply with the study procedures~* In females of childbearing potential, known pregnancy or positive serum/urine pregnancy test~* Breast-feeding woman~* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding enrollment. Planned participation in another clinical trial during the present trial period~* Current alcohol or recreational drug use that may interfere with the subject's ability to comply with trial procedures~* Thrombocytopenia, bleeding disorder, anticoagulation therapy contraindicating intramuscular (IM) vaccination~* Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.~* Other events which in the judgment of the investigator would preclude vaccination at the time of Visit 1 For Group 3~* History of documented diphtheria, pertussis, or tetanus disease since participation in study TD9707 or TD9805~* Known or suspected receipt of a diphtheria-, pertussis-, or tetanus-containing vaccine since participation in study TD9707 or TD9805.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group 1: Previous Tdap or Tdap-IPV Recipients (Type: EXPERIMENTAL): Participants received Tdap or Tdap-Inactivated Poliomyelitis Vaccine (IPV) in a previous study (TD9707 or TD9805)
- Group 2: Tdap vaccine-naïve (Type: ACTIVE_COMPARATOR): Participants are age-balanced Tdap vaccine-naïve and will receive Tdap vaccine in the study at least 10 years after a previous tetanus, diphtheria and/or pertussis dose.
- Group 3 (Type: NO_INTERVENTION): Past participants in Study TD9707 and TD9805 did not qualify for Tdap re-administration in this study or were unwilling to receive a second dose of Tdap. They were not included in the analysis for the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete